Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

HOWL US Equity

Werewolf Therapeutics, Inc.Health Care · Pharmaceutical Preparations · CIK 1785530 · FY ends Dec 31
$0.41
+0.00 (+0.07%)
USD · as of 2026-08-19 · marketstack

Legal & controls

5 of 5 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-03-27none statedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are not currently a party to any material legal proceedings.

Item 9A · ICFR · Based on this assessment as of December 31, 2025, management concluded that our internal control over financial reporting was effective at the reasonable assurance level.

Item 9A · disclosure controls · Based on the evaluation of our disclosure controls and procedures as of December 31, 2025, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

2024-12-312025-03-11none statedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are not currently a party to any material legal proceedings.

Item 9A · ICFR · Based on this assessment as of December 31, 2024, management concluded that our internal control over financial reporting was effective at the reasonable assurance level.

Item 9A · disclosure controls · Based on the evaluation of our disclosure controls and procedures as of December 31, 2024, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

2023-12-312024-03-07none statedNOT effectiveNOT effectivedisclosedEDGAR

Item 3 · We are not currently a party to any material legal proceedings.

Item 9A · ICFR · Based on this assessment as of December 31, 2023, management concluded that our internal control over financial reporting was not effective due to the material weakness discussed below.

Item 9A · disclosure controls · Based on the evaluation of our disclosure controls and procedures as of December 31, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were not effective due to a material weakness in our internal control over financial reporting as discussed below.

2022-12-312023-03-23none statedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are not currently a party to any material legal proceedings.

Item 9A · ICFR · Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2022.

Item 9A · disclosure controls · Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

2021-12-312022-03-24none statedNOT effectiveeffectiveremediated (prior year)EDGAR

Item 3 · We are not currently a party to any material legal proceedings.

Item 9A · ICFR · Remediation of Material Weaknesses Based on our prior assessment as of December 31, 2020, management concluded that our internal control over financial reporting was not effective due to material weaknesses relating to the lack of maintaining a sufficient complement of personnel commensurate with the accounting and financial reporting requirements in order to have adequate segregation of key duties and responsibilities.

Item 9A · disclosure controls · Our principal executive officer and principal financial and accounting officer have concluded based upon the evaluation described above that, as of December 31, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.

5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.